First Results of Avicidin Trials
SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation studies, Avicidin produced a 10-fold improvement in tumor-to-blood ratios over conventional radioimmunotherapy, approaching the ratios achieved in animal studies.
SEATTLE--NeoRx Corporation reports that in phase I/II dose escalationstudies, Avicidin produced a 10-fold improvement in tumor-to-bloodratios over conventional radioimmunotherapy, approaching the ratiosachieved in animal studies.
Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx'sproprietary pretargeting technology in which the radionuclideand antibody are injected separately rather than linked together.The radionuclide either attaches to the antibody that is pretargetedto the tumor or quickly exits the body, reducing radiation exposureto normal tissues, NeoRx said.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
